Colon cancer trial of Vectibix is recruiting

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

Amgen is currently enrolling patients in a phase III study designed to evaluate the effectiveness of panitumumab (Vectibix) in combination with chemotherapy (FOLFIRI)

THOUSAND OAKS, California—Amgen is currently enrolling patients in a phase III study designed to evaluate the effectiveness of panitumumab (Vectibix) in combination with chemotherapy (FOLFIRI), compared with FOLFIRI alone as second-line chemotherapy in patients with previously treated metastatic colorectal cancer.

Vectibix is a fully human anti-EGFR monoclonal antibody. It was FDA approved in 2006 for third-line treatment of metastatic colorectal cancer with disease progression on or following chemotherapy regimens based on fluoropyrimidine, oxaliplatin (Eloxatin), or irinotecan (Camptosar). The approval was based on improved progression-free survival data.

The study is open to men and women whose metastatic disease has progressed while on or following treatment with a standard first-line chemotherapy regimen that includes 5-fluorouracil. Patients must have ECOG performance status of 0-2, radiologically documented disease progression, at least one measurable lesion of at least 20 mm, no prior irinotecan therapy, and no prior anti-EGFR therapy.

Physicians or patients interested in exploring study participation can log on to www.AmgenTrials.com or call 1-800-772-6436 (1-800-77-AMGEN).

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.
Related Content